Novo Nordisk A/s

Philip Jonas Sassene

Andreas Vegge

Jais Rose Bjelke

Thomas Egebjerg

Marie-Ange Buyse

Soren Steffensen

Frantisek Hubalek

Steffen Reedtz-Runge

Mathias Norrman

Simon Bjerregaard

Jorrit Jeroen Water

Evelyn De Tavernier

Per J Greisen

Jacob Lund

Simone Fulle

Emma Balantic-Nielsen

Che Yang

Katharina Luise Maria Kopp

Ulrik Lytt Rahbek

Daniele Granata

The present invention relates to compounds (e.g. ISVDs, polypeptides, polypeptide derivatives) capable of binding to Interleukin-6 (IL-6) and their use in the treatment of inflammatory diseases such as, e.g. cardiovascular disease (CVD).

Anti IL-6 domain antibodies with fatty acid substituents

The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.

Highly potent ISVD compounds capable of substituting for FVIII(A)

The invention relates to pharmaceutical compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.

Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid

Growing community of inventors

Copenhagen, Denmark

Philip Jonas Sassene